caa a22 4500 44533522X CHVBK 20180317142752.0 cr unu---uuuuu 170323e20110301xx s 000 0 eng 10.1245/s10434-010-1366-8 doi (NATIONALLICENCE)springer-10.1245/s10434-010-1366-8 Does Neoadjuvant Bevacizumab Increase Surgical Complications in Breast Surgery? [Elektronische Daten] [M. Golshan, J. Garber, R. Gelman, Nadine Tung, B. Smith, S. Troyan, C. Greenberg, E. Winer, P. Ryan] Background: Neoadjuvant chemotherapy is being increasingly used in operable breast cancer. There are limited data on the safety of bevacizumab (bev) in the neoadjuvant setting. We sought to explore the safety of neoadjuvant cisplatin/bev in a protocol for triple negative breast cancer (TNBC). Materials and Methods: A total of 51 patients with confirmed TNBC were enrolled in a single-arm trial of neoadjuvant cisplatin plus bev. Of the 51 patients, 28 with confirmed TNBC were enrolled in our trial of single-agent neoadjuvant cisplatin. Two-sided Fisher exact test were used for comparing the 2 trials. Results: The 51 patients received neoadjuvant protocol therapy with cisplatin/bev and underwent definitive local therapy. Breast conserving therapy (BCT) was performed in 29 (57%) and mastectomy with or without reconstruction in 22 (43%). Postoperative complications were reported in 22 patients (43%); 4 (8%) required explanation of expanders. Also, 28 patients completed neoadjuvant cisplatin therapy. BCT was performed in 13 (46%) and mastectomy with or without reconstruction in 15 (54%). Postoperative complications were reported in 11 patients (39%). None of the 5 reconstructions were lost. We compared all toxicities between the two trials (P=.81 NS), and wound healing related complications between the two trials (P=.10 NS). Conclusions: Cisplatin/bevacizumab and cisplatin alone neoadjuvant therapy resulted in a significant number of postoperative complications. Specifically, use of expanders/implants may be problematic for patients treated with bev. However, this was a single-arm trial; randomized controlled studies will be needed to determine the optimal use of bevacizumab in the timing of breast cancer surgery. Society of Surgical Oncology, 2010 Golshan M. Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA aut Garber J. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA aut Gelman R. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA aut Tung Nadine Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA aut Smith B. Department of Surgery, Massachusetts General Hospital, Boston, MA, USA aut Troyan S. Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA aut Greenberg C. Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA aut Winer E. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA aut Ryan P. Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA aut Annals of Surgical Oncology Springer-Verlag 18/3(2011-03-01), 733-737 1068-9265 18:3<733 2011 18 10434 https://doi.org/10.1245/s10434-010-1366-8 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1366-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Golshan M. Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA aut NATIONALLICENCE 700 1- Garber J. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA aut NATIONALLICENCE 700 1- Gelman R. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA aut NATIONALLICENCE 700 1- Tung Nadine Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA aut NATIONALLICENCE 700 1- Smith B. Department of Surgery, Massachusetts General Hospital, Boston, MA, USA aut NATIONALLICENCE 700 1- Troyan S. Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA aut NATIONALLICENCE 700 1- Greenberg C. Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA aut NATIONALLICENCE 700 1- Winer E. Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA aut NATIONALLICENCE 700 1- Ryan P. Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/3(2011-03-01), 733-737 1068-9265 18:3<733 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer